Clinical Trial Search

Primary: Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms — 91.2; 88.2 percentage of participants with AE — p=0.003

Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants

Primary: Geometric Mean Concentrations (GMCs) for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies in a Subset of Subjects — 16.704; 18.658; 18.437; 18.112 IU/mL

Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 21.6; 37.9 events/hour of sleep — p=0.56

Primary: Number of Participants With Best Objective Response Rate (ORR) — 46; 46 Participants

Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAE). — 0; 0 Participants

Primary: Patient Quality of Life (QOL), Compared Mean QOL Change From Baseline at Each Follow-up Assessment Between the Clinics Assigned to the Intensive and Standard e-AT…

Primary: Occurrence of Plantar Diabetic Foot Ulcer — 37 Participants

Primary: Renal Clearance (CLr) of Metformin — 32.18; 33.33 litre per hour (L/hr)

Primary: Percent Change From Baseline in Body Weight at Week 26 — -1.76; -8.51; -9.83; -11.80 Percent Change — p=< 0.001

Primary: Migraine Days — 14.267; 14.133; 11.067; 9.867 Days

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Pain (Walking Pain) Subscale Score Over 26 Weeks — -2.271; -2.146 score…

Primary: Changes in Brain Response to Food Cues in the Insula — 0.25; -0.9; -0.01 z-score

Primary: Percent Disease Control Rate (DCR) — 33 percentage of participants

Primary: Change in Score in Worst Pain Over the Last Month — -0.5; -5 score on a scale